Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cybin Inc
N.CYBN
Alternate Symbol(s):
CYBN
Healthcare
Drug Manufacturers - Specialty & Generic
Psychedelics
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary...
deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NEO:CYBN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
(16)
•••
realmccoy
X
View Profile
View Bullboard History
Post by
realmccoy
on Sep 10, 2022 4:20am
Next Shroom Stock to Blow: $Silo 𓋼𓋺📈𓋺𓋼 SILO WELLNESS
Volume says it all. Fidelity has been buying major. News Soon :-D
(3018)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Aug 10, 2022 5:22pm
Microdose Announces The 2nd Annual Microdose Awards
Miami, Florida--(Newsfile Corp. - August 9, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is excited to announce the lineup of categories for the 2nd
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 12, 2022 8:12am
New Press Release - Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 11, 2022 7:30am
New Press Release - Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
-- Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months -- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 27, 2022 7:29pm
New Press Release - Cybin Announces Additional Adelia Milestone Achievement
Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 27, 2022 8:10am
New Press Release - Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
-- Marks the first novel psilocybin analog to enter clinical development -- -- Patient recruitment to commence immediately -- -- Pharmacokinetic and safety data readout expected in Q4 2022 -- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 22, 2022 7:30am
New Press Release - Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
- Company reiterates key pipeline and strategic milestones for 2022 – Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported audited financial results for its fiscal year ended...
read article.
(2)
•••
duginthemud
X
View Profile
View Bullboard History
Comment by
duginthemud
on Jun 18, 2022 1:19pm
RE:RE:Quiet Over Here. New Member needs Advice...
hi gajjardr, would you be able to explain why you feel so sure? anything would be helpful, thanks. dug
(2)
•••
HellsAngels666
X
View Profile
View Bullboard History
Comment by
HellsAngels666
on Jun 16, 2022 4:23pm
RE:RE:Quiet Over Here. New Member needs Advice...
I just took a look at this company suggestion. Nice cheapie. Volume on all Shroom stocks has bottomed out only because people are awaiting the Health Canada studies. It's pretty obvious what will
...more
(100)
•••
GajjarDr
X
View Profile
View Bullboard History
Comment by
GajjarDr
on Jun 16, 2022 2:03pm
RE:Quiet Over Here. New Member needs Advice...
LOBE 100%
(6)
•••
ashleyvandyke
X
View Profile
View Bullboard History
Comment by
ashleyvandyke
on Jun 16, 2022 1:56pm
RE:Quiet Over Here. New Member needs Advice...
# Please type your reply above this line # If your request directly relates to a paid service such as Stockstream we will prioritize your matter and respond same business day between 6:00AM and 10:AM
...more
(15)
•••
fTrudeau
X
View Profile
View Bullboard History
Post by
fTrudeau
on Jun 15, 2022 4:49pm
Quiet Over Here. New Member needs Advice...
What's a better value stock pick for mushrooms? LOBE or this one Cybin ???
(1)
•••
theleak
X
View Profile
View Bullboard History
Post by
theleak
on May 18, 2022 11:24am
check out $nirv
$nirv looks alot more attractive than cybin at the moment. not too mention the CEO is a legend. check them out...only been listed for 3 months
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on May 10, 2022 8:45am
Excellent YT analysis on CYBN
https://youtu.be/9kFe_t-N4Ow
(47)
•••
Minty_33
X
View Profile
View Bullboard History
Post by
Minty_33
on Apr 13, 2022 8:12pm
Solid Close Today....
And respectable volume. I expect the share price to remain strong going into next week with the upcoming Benzinga conference on psychedelics and CYBN CEO as keynote speaker. We shall see but I'm
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.
Growth Rocket 2025 – Why dynaCERT is in the Spotlight